West Announces Leadership Changes
West Pharmaceutical Services (NYSE: WST) announced key executive leadership changes. Bernard J. Birkett, Senior Vice President and Chief Financial Officer, has announced his intention to retire this year after serving since June 2018. The company has initiated a search for his successor, with Birkett remaining as CFO during the transition period.
Additionally, Shane Campbell has been appointed as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025. Campbell joins from Carlisle Companies Inc., where he served as Chief Commercial Officer of the Construction Materials business, bringing 20 years of experience from DuPont in various senior global leadership roles.
During his tenure, Birkett played a important role in helping West navigate through global pandemic challenges, destocking complexities, and the emergence of GLP-1s. In 2022, he served as Chief Financial and Operations Officer before transitioning back to focusing solely on CFO responsibilities in April 2024.
West Pharmaceutical Services (NYSE: WST) ha annunciato importanti cambiamenti nella leadership esecutiva. Bernard J. Birkett, Vicepresidente Senior e Direttore Finanziario, ha comunicato la sua intenzione di andare in pensione entro quest'anno, dopo aver ricoperto il ruolo dal giugno 2018. L'azienda ha avviato la ricerca del suo successore, con Birkett che rimarrà CFO durante il periodo di transizione.
Inoltre, Shane Campbell è stato nominato Vicepresidente Senior e Chief Proprietary Segment Officer, con effetto dal 5 maggio 2025. Campbell arriva da Carlisle Companies Inc., dove ha ricoperto il ruolo di Chief Commercial Officer del settore Materiali da Costruzione, portando con sé 20 anni di esperienza in DuPont in vari ruoli dirigenziali globali di alto livello.
Durante il suo mandato, Birkett ha svolto un ruolo fondamentale nell'aiutare West a gestire le sfide della pandemia globale, le complessità legate al destocking e l’emergere dei GLP-1. Nel 2022, ha ricoperto il ruolo di Chief Financial and Operations Officer prima di tornare a concentrarsi esclusivamente sulle responsabilità di CFO nell’aprile 2024.
West Pharmaceutical Services (NYSE: WST) anunció cambios clave en su liderazgo ejecutivo. Bernard J. Birkett, Vicepresidente Senior y Director Financiero, ha anunciado su intención de retirarse este año tras desempeñarse en el cargo desde junio de 2018. La compañía ha iniciado la búsqueda de su sucesor, con Birkett permaneciendo como CFO durante el período de transición.
Además, Shane Campbell ha sido nombrado Vicepresidente Senior y Chief Proprietary Segment Officer, con efecto a partir del 5 de mayo de 2025. Campbell proviene de Carlisle Companies Inc., donde fue Director Comercial del negocio de Materiales de Construcción, aportando 20 años de experiencia en DuPont en diversos roles globales de liderazgo senior.
Durante su gestión, Birkett jugó un papel importante ayudando a West a enfrentar los desafíos de la pandemia global, las complejidades del destockeo y la aparición de los GLP-1. En 2022, se desempeñó como Director Financiero y de Operaciones antes de volver a centrarse exclusivamente en sus responsabilidades como CFO en abril de 2024.
West Pharmaceutical Services (NYSE: WST)가 주요 경영진 인사 변동을 발표했습니다. Bernard J. Birkett 수석 부사장 겸 최고재무책임자(CFO)는 2018년 6월부터 재직해 왔으며 올해 은퇴할 의사를 밝혔습니다. 회사는 그의 후임자 찾기를 시작했으며, Birkett는 인수인계 기간 동안 CFO 직을 유지할 예정입니다.
또한, Shane Campbell이 2025년 5월 5일부로 수석 부사장 겸 Chief Proprietary Segment Officer로 임명되었습니다. Campbell은 Carlisle Companies Inc. 출신으로, 건축 자재 사업부의 최고 상업 책임자를 역임했으며, DuPont에서 20년간 다양한 글로벌 고위 리더십 역할을 수행한 경험을 가지고 있습니다.
Birkett는 재임 기간 동안 글로벌 팬데믹 위기, 재고 축소의 복잡성, GLP-1의 부상 등에서 West가 성공적으로 대응할 수 있도록 중요한 역할을 했습니다. 2022년에는 최고재무운영책임자(CFO 및 COO)를 역임했으며, 2024년 4월부터는 다시 CFO 업무에 전념하고 있습니다.
West Pharmaceutical Services (NYSE : WST) a annoncé des changements clés dans sa direction exécutive. Bernard J. Birkett, vice-président senior et directeur financier, a annoncé son intention de prendre sa retraite cette année après avoir occupé ce poste depuis juin 2018. La société a lancé la recherche de son successeur, Birkett restant CFO pendant la période de transition.
De plus, Shane Campbell a été nommé vice-président senior et Chief Proprietary Segment Officer, à compter du 5 mai 2025. Campbell rejoint l’entreprise depuis Carlisle Companies Inc., où il était directeur commercial du secteur des matériaux de construction, apportant 20 ans d’expérience chez DuPont dans divers postes de direction mondiale.
Au cours de son mandat, Birkett a joué un rôle important en aidant West à surmonter les défis liés à la pandémie mondiale, aux complexités du déstockage et à l’émergence des GLP-1. En 2022, il a occupé le poste de directeur financier et des opérations avant de se recentrer uniquement sur ses fonctions de CFO en avril 2024.
West Pharmaceutical Services (NYSE: WST) hat bedeutende Änderungen in der Geschäftsleitung bekannt gegeben. Bernard J. Birkett, Senior Vice President und Chief Financial Officer, hat seine Absicht angekündigt, in diesem Jahr in den Ruhestand zu gehen, nachdem er seit Juni 2018 im Amt war. Das Unternehmen hat die Suche nach seinem Nachfolger eingeleitet, wobei Birkett während der Übergangsphase als CFO tätig bleibt.
Darüber hinaus wurde Shane Campbell zum Senior Vice President und Chief Proprietary Segment Officer mit Wirkung zum 5. Mai 2025 ernannt. Campbell kommt von Carlisle Companies Inc., wo er als Chief Commercial Officer des Geschäftsbereichs Baustoffe tätig war und 20 Jahre Erfahrung bei DuPont in verschiedenen globalen Führungspositionen mitbringt.
Während seiner Amtszeit spielte Birkett eine wichtige Rolle dabei, West durch die Herausforderungen der globalen Pandemie, die Komplexitäten beim Abbau von Lagerbeständen und das Aufkommen von GLP-1 zu navigieren. Im Jahr 2022 war er Chief Financial and Operations Officer, bevor er im April 2024 wieder ausschließlich die CFO-Verantwortung übernahm.
- Planned smooth leadership transition with current CFO staying until successor is appointed
- Appointment of experienced executive Shane Campbell as Chief Proprietary Segment Officer
- Successful navigation through major business challenges under Birkett's leadership
- Departure of veteran CFO Bernard Birkett who helped navigate critical business periods
Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor
Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer
- Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this year. West has commenced a search for a successor. Mr. Birkett and West plan for him to remain as CFO until his successor is in place, and as an advisor to West in order to facilitate a seamless transition.
- Shane Campbell has been appointed to serve as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025.
CFO Transition
"On behalf of all of us at West, I want to thank Bernard for his strong contributions and leadership over the past seven years. He has been an invaluable partner and advisor to me and the entire leadership team," said Eric M. Green, President, Chief Executive Officer and Chair of the Board. "Bernard played a critical role along with the Finance and Global Operations teams, in helping West navigate the challenges of the global pandemic, the complexities of destocking, and the emergence of GLP-1s. He has been instrumental in our continued growth, and I look forward to his support as we search for his successor."
"After great consideration, I have decided to bring my tenure at West to a close in order to pursue new endeavors. It has been an honor to serve as the CFO of West, making a positive difference on patients' lives," Mr. Birkett said. "West has exceptional people, and I want to thank our talented team for all that we have accomplished together."
Mr. Birkett joined West as Senior Vice President and Chief Financial Officer in June 2018. In 2022, he was appointed to the combined role of Chief Financial and Operations Officer. In April 2024, he transitioned back to focusing solely on his responsibilities as Chief Financial Officer. Mr. Birkett's contributions have been pivotal in strengthening West's financial and business profile.
Chief Proprietary Segment Officer Appointment
Mr. Campbell joins West from Carlisle Companies Inc., where he served as Chief Commercial Officer of the Construction Materials business. As an accomplished leader, Mr. Campbell brings extensive global management experience across operations, engineering, commercial and strategy. Over a 20-year career at DuPont, Mr. Campbell served in a number of senior global leadership roles focused in the areas of elastomers, polymers, building materials, chemicals, packaging and safety.
"We are thrilled to welcome Shane to our team at West," said Mr. Green. "His extensive industry experience and strategic vision will be invaluable as we continue to drive our Proprietary Products strategy and ensure West achieves its long-term growth and success."
"I am excited to join West and work alongside such a talented team that is dedicated to improving patient health," said Mr. Campbell. "With a legacy of over a century of innovation, West is well-positioned to sustain its success well into the future, and I look forward to contributing to the tradition of excellence that pervades the Company."
First-Quarter 2025 Results
In a separate press release issued today, West announced its first-quarter 2025 financial results. The Company will host a conference call at 9:00 a.m. Eastern Time to discuss the results and business expectations.
The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call.
Forward-Looking Statements
Certain statements in this release, including statements regarding the intent of Mr. Birkett to retire from his position as CFO of the Company and the plans for identifying his successor, are forward-looking statements. These statements are subject to risks and uncertainties, such as the timing required for the Company to identify a successor to Mr. Birkett and reflect management's current expectations. The statements speak only as of the date of this release and the Company undertakes no obligations to update these statements.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.
Headquartered in
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
View original content to download multimedia:https://www.prnewswire.com/news-releases/west-announces-leadership-changes-302436654.html
SOURCE West Pharmaceutical Services, Inc.
FAQ
When will Bernard Birkett retire as CFO of West Pharmaceutical Services (WST)?
Who is the new Chief Proprietary Segment Officer at West Pharmaceutical Services (WST)?
What major challenges did WST face during Bernard Birkett's tenure as CFO?
What is Shane Campbell's professional background before joining WST?
